• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Royalty Pharma Appoints Vlad Coric, M.D. to the Company's Board of Directors

    4/8/25 4:15:00 PM ET
    $RPRX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $RPRX alert in real time by email

    NEW YORK, April 08, 2025 (GLOBE NEWSWIRE) -- Royalty Pharma plc (NASDAQ:RPRX) today announced the appointment of Vlad Coric, M.D. to the company's Board of Directors, effective immediately. Vlad Coric is the Chairman and Chief Executive Officer of Biohaven, a biopharmaceutical company focused on the discovery, development and commercialization of life-changing treatments in key therapeutic areas including neuroscience, immunology and oncology.

    "I am excited to announce that we are strengthening our Board with the appointment of Vlad Coric," said Pablo Legorreta, founder and Chief Executive Officer of Royalty Pharma. "Vlad's entrepreneurial approach and outstanding leadership skills, honed over a distinguished career in biopharma, will serve as tremendous assets to Royalty Pharma. In addition, Vlad brings notable experience in the royalty funding space, having completed multiple transactions with us during his tenure at Biohaven. We look forward to leveraging his scientific expertise and insights to advance our position as the leading partner funding innovation in life sciences."

    Dr. Coric successfully led Biohaven through the FDA approval and launch of Nurtec ODT for the treatment of migraine. Under his leadership, the company also filed an NDA for its second drug candidate, zavegepant, as the first intranasal CGRP antagonist for ultra-rapid relief of migraine. During his tenure, Dr. Coric oversaw Biohaven's impressive growth from its founding through its sale to Pfizer in May of 2022 for approximately $13 billion in total consideration.

    Dr. Coric has more than 20 years of drug discovery and clinical development experience at Yale School of Medicine and Bristol-Myers Squibb prior to leading Biohaven. Within the pharmaceutical industry, Dr. Coric has expertise working across therapeutic areas including neurology, psychiatry, immunology, virology, oncology and immuno-oncology. During his career, he has been involved in multiple drug development programs. Dr. Coric completed his postdoctoral internship, residency and fellowship at Yale School of Medicine, earned his medical degree from Wake Forest University School of Medicine and was an honors scholar in neurobiology and physiology at the University of Connecticut, where he received his Bachelor of Science degree.

    About Royalty Pharma

    Founded in 1996, Royalty Pharma is the largest buyer of biopharmaceutical royalties and a leading funder of innovation across the biopharmaceutical industry, collaborating with innovators from academic institutions, research hospitals and non-profits through small and mid-cap biotechnology companies to leading global pharmaceutical companies. Royalty Pharma has assembled a portfolio of royalties which entitles it to payments based directly on the top-line sales of many of the industry's leading therapies. Royalty Pharma funds innovation in the biopharmaceutical industry both directly and indirectly – directly when it partners with companies to co-fund late-stage clinical trials and new product launches in exchange for future royalties, and indirectly when it acquires existing royalties from the original innovators. Royalty Pharma's current portfolio includes royalties on more than 35 commercial products, including Vertex's Trikafta, GSK's Trelegy, Roche's Evrysdi, Johnson & Johnson's Tremfya, Biogen's Tysabri and Spinraza, AbbVie and Johnson & Johnson's Imbruvica, Astellas and Pfizer's Xtandi, Novartis' Promacta, Pfizer's Nurtec ODT and Gilead's Trodelvy, and 15 development-stage product candidates. For more information, visit www.royaltypharma.com.   

    Royalty Pharma Investor Relations and Communications

    +1 (212) 883-6637

    [email protected]



    Primary Logo

    Get the next $RPRX alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $RPRX

    DatePrice TargetRatingAnalyst
    5/16/2025$51.00Overweight
    Morgan Stanley
    6/3/2024$28.00Buy → Neutral
    UBS
    6/14/2022$47.00Buy
    UBS
    5/13/2022$53.00Sector Outperform
    Scotiabank
    4/27/2022$56.00Buy
    Goldman
    4/14/2022$50.00Neutral → Overweight
    JP Morgan
    4/6/2022$48.00Overweight
    Morgan Stanley
    10/29/2021$50.00Neutral → Buy
    Citigroup
    More analyst ratings

    $RPRX
    SEC Filings

    See more
    • SEC Form SCHEDULE 13D filed by Royalty Pharma plc

      SCHEDULE 13D - Royalty Pharma plc (0001802768) (Subject)

      5/23/25 5:05:26 PM ET
      $RPRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Royalty Pharma plc filed SEC Form 8-K: Completion of Acquisition or Disposition of Assets, Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation

      8-K - Royalty Pharma plc (0001802768) (Filer)

      5/19/25 5:22:18 PM ET
      $RPRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form S-8 filed by Royalty Pharma plc

      S-8 - Royalty Pharma plc (0001802768) (Filer)

      5/16/25 4:24:25 PM ET
      $RPRX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $RPRX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Fernandez Henry A was granted 1,064 units of Class A Ordinary Shares, increasing direct ownership by 2% to 65,324 units (SEC Form 4)

      4 - Royalty Pharma plc (0001802768) (Issuer)

      6/30/25 5:06:05 PM ET
      $RPRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Bassler Bonnie L was granted 1,064 units of Class A Ordinary Shares, increasing direct ownership by 2% to 71,118 units (SEC Form 4)

      4 - Royalty Pharma plc (0001802768) (Issuer)

      6/30/25 5:04:29 PM ET
      $RPRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by EVP & Vice Chairman Hite Christopher

      4 - Royalty Pharma plc (0001802768) (Issuer)

      5/20/25 4:54:54 PM ET
      $RPRX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $RPRX
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Royalty Pharma and Revolution Medicines Enter Into Funding Agreements for Up to $2 Billion

      Up to $1.25 billion ($250 million upfront) of synthetic royalty funding and up to $750 million in secured debt Innovative partnership enables Revolution Medicines to retain control over pipeline development and global commercialization of daraxonrasib Highlights Royalty Pharma's unique ability to provide capital at scale to help leading companies achieve their strategic goalsDaraxonrasib, in Phase 3 development for pancreatic cancer and non-small cell lung cancer, would be the first targeted therapy to inhibit all major forms of RAS, one of the most common drivers of human cancers NEW YORK, June 24, 2025 (GLOBE NEWSWIRE) -- Royalty Pharma plc (NASDAQ:RPRX) today announced a $2 billi

      6/24/25 7:05:00 AM ET
      $RPRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Royalty Pharma to Present at the Goldman Sachs 46th Annual Global Healthcare Conference

      NEW YORK, June 04, 2025 (GLOBE NEWSWIRE) -- Royalty Pharma plc (NASDAQ:RPRX) today announced that it will participate in a fireside chat at the Goldman Sachs 46th Annual Global Healthcare Conference on Tuesday, June 10, 2025 at 2:00 p.m. ET. The webcast will be accessible from Royalty Pharma's "Events" page at https://www.royaltypharma.com/investors/events/. The webcast will also be archived for a minimum of thirty days. About Royalty Pharma Founded in 1996, Royalty Pharma is the largest buyer of biopharmaceutical royalties and a leading funder of innovation across the biopharmaceutical industry, collaborating with innovators from academic institutions, research hospitals and non-profi

      6/4/25 4:15:00 PM ET
      $RPRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Royalty Pharma Completes the Acquisition of Its External Manager

      NEW YORK, May 16, 2025 (GLOBE NEWSWIRE) -- Royalty Pharma plc (NASDAQ:RPRX) today announced that it has successfully closed the acquisition of its external manager, RP Management, LLC ("RP Management"). The acquisition received overwhelming support from Royalty Pharma's shareholders, with 99.9% of votes cast in favor of the transaction. "The completion of the internalization marks an exciting new chapter for Royalty Pharma," said Pablo Legorreta, founder and Chief Executive Officer. "It reinforces our commitment to transparency, accountability and long-term growth, while better positioning us to fund the significant capital needs and exciting innovation happening in the life sciences indu

      5/16/25 4:30:00 PM ET
      $RPRX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $RPRX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Morgan Stanley initiated coverage on Royalty Pharma with a new price target

      Morgan Stanley initiated coverage of Royalty Pharma with a rating of Overweight and set a new price target of $51.00

      5/16/25 8:05:49 AM ET
      $RPRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Royalty Pharma downgraded by UBS with a new price target

      UBS downgraded Royalty Pharma from Buy to Neutral and set a new price target of $28.00

      6/3/24 9:17:33 AM ET
      $RPRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • UBS resumed coverage on Royalty Pharma with a new price target

      UBS resumed coverage of Royalty Pharma with a rating of Buy and set a new price target of $47.00

      6/14/22 7:27:46 AM ET
      $RPRX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $RPRX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Royalty Pharma plc

      SC 13G/A - Royalty Pharma plc (0001802768) (Subject)

      11/8/24 3:15:49 PM ET
      $RPRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13D/A filed by Royalty Pharma plc

      SC 13D/A - Royalty Pharma plc (0001802768) (Subject)

      7/29/24 4:30:11 PM ET
      $RPRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Royalty Pharma plc (Amendment)

      SC 13G/A - Royalty Pharma plc (0001802768) (Subject)

      2/13/24 10:17:30 AM ET
      $RPRX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $RPRX
    Financials

    Live finance-specific insights

    See more
    • Royalty Pharma and Revolution Medicines Enter Into Funding Agreements for Up to $2 Billion

      Up to $1.25 billion ($250 million upfront) of synthetic royalty funding and up to $750 million in secured debt Innovative partnership enables Revolution Medicines to retain control over pipeline development and global commercialization of daraxonrasib Highlights Royalty Pharma's unique ability to provide capital at scale to help leading companies achieve their strategic goalsDaraxonrasib, in Phase 3 development for pancreatic cancer and non-small cell lung cancer, would be the first targeted therapy to inhibit all major forms of RAS, one of the most common drivers of human cancers NEW YORK, June 24, 2025 (GLOBE NEWSWIRE) -- Royalty Pharma plc (NASDAQ:RPRX) today announced a $2 billi

      6/24/25 7:05:00 AM ET
      $RPRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Royalty Pharma Completes the Acquisition of Its External Manager

      NEW YORK, May 16, 2025 (GLOBE NEWSWIRE) -- Royalty Pharma plc (NASDAQ:RPRX) today announced that it has successfully closed the acquisition of its external manager, RP Management, LLC ("RP Management"). The acquisition received overwhelming support from Royalty Pharma's shareholders, with 99.9% of votes cast in favor of the transaction. "The completion of the internalization marks an exciting new chapter for Royalty Pharma," said Pablo Legorreta, founder and Chief Executive Officer. "It reinforces our commitment to transparency, accountability and long-term growth, while better positioning us to fund the significant capital needs and exciting innovation happening in the life sciences indu

      5/16/25 4:30:00 PM ET
      $RPRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Royalty Pharma Announces Shareholder Approval of its External Manager Acquisition

      Received overwhelming shareholder approval with 99.9% of votes cast in favorSimplified structure benefits shareholders through strengthened shareholder alignment, enhanced governance, significant cash savings and increased economic return on investments Significant annual cash savings of greater than $100 million in 2026 growing to over $175 million in 2030, with cumulative savings of more than $1.6 billion over ten yearsRoyalty Pharma's diversified royalty portfolio to be combined with intellectual capital and investment platform of the Manager to advance shareholder value creation NEW YORK, May 12, 2025 (GLOBE NEWSWIRE) -- Royalty Pharma plc (NASDAQ:RPRX) today announced that sharehold

      5/12/25 4:15:00 PM ET
      $RPRX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $RPRX
    Leadership Updates

    Live Leadership Updates

    See more
    • Royalty Pharma Appoints Vlad Coric, M.D. to the Company's Board of Directors

      NEW YORK, April 08, 2025 (GLOBE NEWSWIRE) -- Royalty Pharma plc (NASDAQ:RPRX) today announced the appointment of Vlad Coric, M.D. to the company's Board of Directors, effective immediately. Vlad Coric is the Chairman and Chief Executive Officer of Biohaven, a biopharmaceutical company focused on the discovery, development and commercialization of life-changing treatments in key therapeutic areas including neuroscience, immunology and oncology. "I am excited to announce that we are strengthening our Board with the appointment of Vlad Coric," said Pablo Legorreta, founder and Chief Executive Officer of Royalty Pharma. "Vlad's entrepreneurial approach and outstanding leadership skills, hon

      4/8/25 4:15:00 PM ET
      $RPRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Royalty Pharma Appoints Molly Sawaya as Executive Vice President, Head of Human Capital

      NEW YORK, July 24, 2024 (GLOBE NEWSWIRE) -- Royalty Pharma plc (NASDAQ:RPRX) today announced the appointment of Molly Sawaya as Executive Vice President, Head of Human Capital. Molly joins Royalty Pharma from Hudson Bay Capital, where she was a Managing Director and Head of Colleague Experience, responsible for designing and delivering the firm's Human Resources (HR) agenda, including onboarding, colleague engagement, professional development, compensation and benefits. Previously, Molly held a number of global HR roles of increasing responsibility at QBE Insurance Group, Perpetual Limited and National Australia Bank. Molly received her Bachelor of Arts and Master of Applied Science deg

      7/24/24 8:30:00 AM ET
      $RPRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Royalty Pharma Appoints Eric Schneider as Chief Technology Officer

      NEW YORK, Sept. 21, 2023 (GLOBE NEWSWIRE) -- Royalty Pharma plc (NASDAQ:RPRX) today announced the appointment of Eric Schneider as Senior Vice President, Chief Technology Officer. Eric will also join Royalty Pharma's Senior Leadership Committee. Eric joins Royalty Pharma from Verisk, a global leader in data-driven analytic insights and solutions, where he was a Senior Vice President, Chief Data Officer and Chief Technology Officer, and a member of the Executive Leadership Team. During his tenure at Verisk, he led their migration to the cloud, mainframe modernization strategy and Data Governance and Data Strategy Team. Prior to Verisk, Mr. Schneider held senior IT leadership roles at Moody

      9/21/23 8:25:00 AM ET
      $RPRX
      Biotechnology: Pharmaceutical Preparations
      Health Care